• Careers
  • Apply
  • Events
    • Global
    • Local
  • News
  • Partner Stories
  • Contact
  • Careers
  • Apply
  • Events
    • Global
    • Local
  • News
  • Partner Stories
  • Contact
24
Jun

Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer

Preliminary Clinical Trial, Prostate cancer

An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial.

PrevNext

Related Posts

February 16, 2023

MRI-Guided RT Reduced Acute Toxic Effects in Men With Localised Prostate Cancer

increaseoNews0
January 28, 2023

MRI-Targeted Biopsy for Prostate Cancer Reduces Risk of Overdiagnosis

increaseoNews0
January 10, 2023

Can Oncologists Reduce the Suicide Risk in Their Prostate Cancer Patients?

increaseoNews0

About Us

GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. Gloreen G at GCG has vast experience and understanding of the specialist medical and diagnostic imaging market. This gives GCG the ability to ensure that you receive the very best salary and incentives package, including leave entitlements, days off, paid conferences and radiology expenses.

Latest News

  • Google Health, radiology vendor seek regulatory approval of AI as independent mammography reader
  • Interventional echocardiography expected to grow thanks to new structural heart procedures
  • Retinal OCT Shows Promise as Diagnostic Aid for Mild Cognitive Impairment
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
© GCG Global Healthcare Pty Ltd, All rights reserved. ABN 25 136 716 991

Find your next opportunity with
GCG Global Healthcare TODAY!

DISCOVER OUR OPEN POSITIONS NOW!